Ipsen appoints new Executive Vice President

pharmafile | March 2, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ipsen 

Ipsen has announced the appointment of Benoit Hennion as Executive Vice President and President of Primary Care. Hennion has worked for Ipsen for the last 11 years, working his way from Corporate Strategic Planning Director & ComEx Secretary to General Manager for France Commercial Operations, before his current appointment.

Hennion will begin his new role on 13 March, leaving his previous position as Vice President, Asia-Pacific for Specialty Care. He will enter the role after the previous incumbent, Jean Fabre, leaving the position to “pursue a new career opportunity at another company”, according to the press release.

David Meek, CEO of Ipsen, commented on the new appointment: “I would like to acknowledge the tremendous contribution made by Jean Fabre, who has been with our company for nearly a decade. It is my great pleasure to welcome his successor, Benoit Hennion, to the Executive Leadership Team as Executive Vice President and President, Primary Care. Throughout his 11 years at Ipsen, Benoit has consistently demonstrated his strategic vision and ability to drive change. His thorough knowledge of Ipsen’s Primary Care portfolio, together with his broad, international leadership experience and indisputable leadership skills, will enable Benoit to play a central role in the ongoing transformation of our global Primary Care operations into a sustainable business focused on meeting our patients’ needs.”

Related Content

Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment

Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) …

FDA accepts Ipsen’s NDA for ultra-rare genetic disorder drug

The FDA have accepted Ipsen’s New Drug Application (NDA) for palovarotene, an oral, investigational, selective …

Latest content